(NASDAQ: NKTX) Nkarta's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.81%.
Nkarta's earnings in 2025 is -$102,610,000.On average, 9 Wall Street analysts forecast NKTX's earnings for 2025 to be -$98,411,389, with the lowest NKTX earnings forecast at -$98,148,580, and the highest NKTX earnings forecast at -$99,192,714. On average, 9 Wall Street analysts forecast NKTX's earnings for 2026 to be -$97,445,388, with the lowest NKTX earnings forecast at -$114,854,721, and the highest NKTX earnings forecast at -$79,801,657.
In 2027, NKTX is forecast to generate -$68,287,773 in earnings, with the lowest earnings forecast at -$128,080,416 and the highest earnings forecast at $89,497,185.